ODYSSEY LONG TERM - Long term results underscore efficacy and safety of alirocumab for lowering cholesterol

BARCELONA, Spain – Sunday 31 August: Long term results for the investigational monoclonal antibody alirocumab, show that in addition to significantly reducing cholesterol on top of regular statin therapy, it also reduced the incidence of cardiovascular events, researchers reported in a Hot Line session today at ESC Congress 2014.

Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...